SOUTH SAN FRANCISCO, Calif.,—Kezar Life Sciences has reported its second-quarter 2025 financial results alongside a notable series of regulatory and clinical advancements for zetomipzomib, its selective immunoproteasome inhibitor in development for autoimmune hepatitis (AIH). The company confirmed the FDA’s removal of the partial clinical hold on the completed Phase 2a PORTOLA trial, submission of a Type C meeting request for Q4 2025, and the selection of PORTOLA data for oral presentation at The Liver Meeting® 2025, signaling renewed momentum in its AIH program.
Science Significance
The scientific importance of this update lies in the growing body of evidence suggesting zetomipzomib’s potential to offer a disease-modifying, steroid-sparing therapy for patients with autoimmune hepatitis, a population that often struggles with treatment-related toxicity and limited therapeutic innovation. The PORTOLA Phase 2a topline data demonstrated that 36% of patients achieved a complete biochemical response with significant steroid tapering, compared to 0% in the placebo arm, while maintaining a favorable safety profile across the blinded six-month period. These findings underscore the mechanism of selective immunoproteasome inhibition as a promising and differentiated approach to managing chronic immune-driven diseases and reinforce interest in advancing toward a registration-enabling clinical development pathway.
Regulatory Significance
From a regulatory standpoint, the FDA’s removal of the partial clinical hold on PORTOLA is a consequential milestone that restores uninterrupted momentum to the zetomipzomib program. Kezar’s formal Type C meeting request aims to secure alignment on the design of a potential registration-enabling trial, a key requirement for advancing toward a future New Drug Application (NDA). In parallel, the submission of a complete response to address the clinical hold in lupus nephritis highlights the company’s ongoing effort to maintain regulatory readiness across multiple indications. These steps collectively position Kezar for a critical period of regulatory engagement, data-driven planning, and risk-managed progression toward late-stage development.
Business Significance
Advertisement
Kezar ended Q2 2025 with $100.8 million in cash, cash equivalents, and marketable securities, providing operational runway to support ongoing clinical, regulatory, and organizational activities. The company reported a reduction in R&D expenses, reflecting the natural winding down of certain trial activities, and a decrease in G&A costs linked to controlled personnel and compensation expenditures. The promotion of Zung To to Chief Development Officer, a veteran with more than three decades of industry leadership, strengthens the executive team at a time when experienced clinical and regulatory oversight is essential. Despite reporting a net loss of $13.7 million, the narrowing deficit compared with 2024 demonstrates financial discipline while prioritizing the zetomipzomib program as the organization’s strategic core.
Patients’ Significance
For patients with autoimmune hepatitis, the developments reported this quarter carry substantial weight. Current AIH therapies often rely on prolonged steroid use, leading to significant side effects and treatment discontinuation. The PORTOLA results indicate that zetomipzomib may offer a safer, more effective, and more durable therapeutic pathway, with responders experiencing extended biochemical remission and no disease flares over the observed period. The inclusion of PORTOLA data in a prestigious oral presentation at The Liver Meeting® 2025 further validates the importance of this research to the clinical community and signals real momentum toward delivering new treatment options for underserved liver-disease patients.
Policy Significance
The progression of zetomipzomib also intersects with broader health policy themes, including the need for innovative therapies for rare and immune-mediated diseases and the drive to enhance regulatory efficiency for promising clinical programs. The FDA’s decision to lift the partial hold reflects confidence in the safety and development strategy, while the upcoming Type C meeting underscores the structured, collaborative nature of modern regulatory science. As agencies continue incentivizing breakthroughs in chronic and underserved disease areas, programs like zetomipzomib demonstrate how regulatory clarity, scientific rigor, and strong clinical design support national goals in therapeutic innovation and patient access.
Kezar Life Sciences’ second-quarter update reveals a company moving decisively to advance a potentially first-in-class therapy for autoimmune hepatitis, backed by improving regulatory traction, promising clinical data, and strengthened operational leadership. With key FDA interactions planned for late 2025 and high-visibility scientific presentations upcoming, Kezar enters the next quarter positioned to shape the future development pathway of zetomipzomib and potentially bring transformative treatment options to patients with chronic immune-mediated disease.
Source: Kezar Life Sciences, Inc. press release
